key: cord-0831036-jrm9aj73 authors: Patrizio, Armando; Ferrari, Silvia Martina; Antonelli, Alessandro; Fallahi, Poupak title: Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination date: 2022-04-09 journal: Autoimmun Rev DOI: 10.1016/j.autrev.2022.103096 sha: fc9de53b8c381be8291018f0f293af51e35d51f8 doc_id: 831036 cord_uid: jrm9aj73 More reports are documenting how vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could represent new external triggers for autoimmune endocrine diseases (AIED) in patients with individual predisposition. We report two cases of Graves' Ophthalmopathy (GO) recrudescence few days after the administration of BNT162B2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Even if causality relationship cannot be excluded, the development of these events could be explained through immune mediated mechanism such as the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). While further investigations are necessary to improve our knowledge of the underlying pathogenesis of these phenomena, caution may be warranted when vaccinating individuals with known autoimmune diseases. Rubinstein has reported a case of new onset GO after 3 days later the administration of the second dose of BNT162B2 SARS-CoV-2 vaccine in a female patient with history of stable GD treated with radioactive iodine more than 10 years before [8] . As in that case, also our patients showed normal thyroid function, elevation of TRAb levels and no new alternative triggering environmental factors such as novel hyperthyroidism flare, pregnancy status, smoking status, or any recent surgery. Moreover, their GO were stable as documented by several follow-up visits at our clinic. Coincidental occurrence of GO and the vaccine administration cannot be excluded, but, just as the previous cases of autoimmune thyroiditis following the SARS-CoV-2 immunization, the close temporal relationship between these two events raises questions about the potential immune stimulation elicited by the vaccine injection in a predisposed person. To date these are the first descriptions of GO worsening following the administration of the BNT162B2 SARS-CoV-2 vaccine. There are no funding sources associated with the writing of this manuscript. Written consent for publication was obtained from the patient. Silvia Martina Ferrari (silvia.ferrari@unipi.it), Alessandro Antonelli (alessandro.antonelli@med.unipi.it) Maintaining Safety with SARS-CoV-2 New-onset autoimmune phenomena post-COVID-19 vaccination CoV-2 vaccination: An aoutoimmune/inflammatory syndrome induced by adjuvants Two further cases of Graves' disease following SARS-CoV-2 vaccination ASIA' -Autoimmune/inflammatory syndrome induced by adjuvants mRNA vaccine era-mechanisms, drug platform and clinical prospection Thyroid eye eisease following COVID-19 vaccine in a patient with a history Graves' disease: a case report The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.